← Leaderboards
Stuart M Levitz
Duke University
$22,736,478
Attributed
$27,724,744
Total exposure
14
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,724,744 · 14
By mechanism
R01$26,002,012 · 8
R24$1,193,457 · 1
R21$452,375 · 1
R13$45,000 · 3
R03$31,900 · 1
Top collaborators
- Charles A Specht12 shared
- Jennifer K. Lodge10 shared
Most similar at Duke University
Same institution · by research overlap
- Jennifer K. Lodge$14,326,240
- Joseph Heitman$44,576,851
- Charles A Specht$2,607,227
- Thomas G. Mitchell$8,151,291
- J. Andrew Alspaugh$11,680,321
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseCryptococcus NeoformansT-LymphocyteImmune ResponseInfectionCytokineVaccinesAntigensFundingCd4 Positive T LymphocytesMediatingVaccinationPersonsFungusVaccine DevelopmentImmuneDendritic CellsYeastsRecombinantsCryptococcosisVaccinatedBaseReceptorCells
Grant awards (66)
Fungal Antigen Resources for Development of Vaccines and Diagnostics$1,193,457
R24 · FY2025 · AI · contact PI
Preclinical studies of a Cryptococcus vaccine for AIDS patients$769,284
R01 · FY2025 · AI
A subunit Cryptococcus vaccine$619,839
R01 · FY2025 · AI · contact PI
Preclinical studies of a Cryptococcus vaccine for AIDS patients$793,078
R01 · FY2024 · AI
A subunit Cryptococcus vaccine$619,839
R01 · FY2024 · AI · contact PI
Preclinical studies of a Cryptococcus vaccine for AIDS patients$793,078
R01 · FY2023 · AI
A subunit Cryptococcus vaccine$619,839
R01 · FY2023 · AI · contact PI
Preclinical studies of a Cryptococcus vaccine for AIDS patients$753,820
R01 · FY2022 · AI
A subunit Cryptococcus vaccine$619,839
R01 · FY2022 · AI · contact PI
Preclinical studies of a Cryptococcus vaccine for AIDS patients$799,003
R01 · FY2021 · AI
The contribution of eosinophils and the IL-23/IL-17 axis to host responses to Aspergillus$418,750
R01 · FY2021 · AI · contact PI
Preclinical studies of a Cryptococcus vaccine for AIDS patients$644,346
R01 · FY2020 · AI
The contribution of eosinophils and the IL-23/IL-17 axis to host responses to Aspergillus$418,750
R01 · FY2020 · AI · contact PI
Preclinical studies of a Cryptococcus vaccine for AIDS patients$644,346
R01 · FY2019 · AI
Immune Response to Cryptococcal Infections$492,500
R01 · FY2019 · AI · contact PI
The contribution of eosinophils and the IL-23/IL-17 axis to host responses to Aspergillus$418,750
R01 · FY2019 · AI · contact PI
Preclinical studies of a Cryptococcus vaccine for AIDS patients$644,346
R01 · FY2018 · AI
Immune Response to Cryptococcal Infections$492,500
R01 · FY2018 · AI · contact PI
The contribution of eosinophils and the IL-23/IL-17 axis to host responses to Aspergillus$418,750
R01 · FY2018 · AI · contact PI
Preclinical studies of a Cryptococcus vaccine for AIDS patients$644,346
R01 · FY2017 · AI
Immune Response to Cryptococcal Infections$492,500
R01 · FY2017 · AI · contact PI
Preclinical studies of a Cryptococcus vaccine for AIDS patients$657,471
R01 · FY2016 · AI
Glucan Particles as a Vaccine Platform for Protective Immunity$541,614
R01 · FY2016 · AI · contact PI
Immune Response to Cryptococcal Infections$492,500
R01 · FY2016 · AI · contact PI
Interactions of pDCs with Aspergilus$418,750
R01 · FY2016 · HL · contact PI
Glucan Particles as a Vaccine Platform for Protective Immunity$541,614
R01 · FY2015 · AI · contact PI
Immune Response to Cryptococcal Infections$492,500
R01 · FY2015 · AI · contact PI
Interactions of pDCs with Aspergilus$412,468
R01 · FY2015 · HL · contact PI
Glucan Particles as a Vaccine Platform for Protective Immunity$542,157
R01 · FY2014 · AI · contact PI
Interactions of pDCs with Aspergilus$408,334
R01 · FY2014 · HL · contact PI
Glucan Particles as a Vaccine Platform for Protective Immunity$524,498
R01 · FY2013 · AI · contact PI
Interactions of pDCs with Aspergilus$415,209
R01 · FY2013 · HL · contact PI
2013 Immunology of Fungal Infections GRC and GRS$5,000
R13 · FY2013 · AI · contact PI
Immune Response to Cryptococcal Infections$403,066
R01 · FY2012 · AI · contact PI
Immunostimulatory properties of chitin and chitosan$205,625
R21 · FY2012 · AI · contact PI
Immune Response to Cryptococcal Infections$403,066
R01 · FY2011 · AI · contact PI
Immunostimulatory properties of chitin and chitosan$246,750
R21 · FY2011 · AI · contact PI
2011 Immunology of Fungal Infections Gordon Research Conference$20,000
R13 · FY2011 · AI · contact PI
Immune Response to Cryptococcal Infections$407,034
R01 · FY2010 · AI · contact PI
Immune Response to Cryptococcal Infections$409,896
R01 · FY2009 · AI · contact PI
Model Vaccines Exploiting Fungal Mannosylation$402,324
R01 · FY2009 · AI · contact PI
Immune Response to Cryptococcal Infections$408,542
R01 · FY2008 · AI · contact PI
Model Vaccines Exploiting Fungal Mannosylation$340,093
R01 · FY2008 · AI · contact PI
Model Vaccines Exploiting Fungal Mannosylation$55,219
R01 · FY2008 · AI · contact PI
Immune Response to Cryptococcal Infections$346,679
R01 · FY2007 · AI · contact PI
Model Vaccines Exploiting Fungal Mannosylation$346,679
R01 · FY2007 · AI · contact PI
Immune Response to Cryptococcal Infections$338,232
R01 · FY2006 · AI · contact PI
Model Vaccines Exploiting Fungal Mannosylation$266,075
R01 · FY2006 · AI · contact PI
Model Vaccines Exploiting Fungal Mannosylation$87,663
R01 · FY2006 · AI · contact PI
Immune Response to Cryptococcal Infections$15,506
R01 · FY2006 · AI · contact PI
Immune Response to Cryptococcal Infections$362,250
R01 · FY2005 · AI
MACROPHAGE INTERACTIONS WITH C. NEOFORMANS$315,000
R01 · FY2005 · AI
Model Vaccines Exploiting Fungal Mannosylation$307,913
R01 · FY2005 · AI
6th International Conf. on Cryptococcus &Cryptococcosis$20,000
R13 · FY2005 · AI
Immune Response to Cryptococcal Infections$362,250
R01 · FY2004 · AI
MACROPHAGE INTERACTIONS WITH C. NEOFORMANS$315,000
R01 · FY2004 · AI
MACROPHAGE INTERACTIONS WITH C. NEOFORMANS$369,752
R01 · FY2003 · AI
Immune Response to Cryptococcal Infections$181,125
R01 · FY2003 · AI
MACROPHAGE INTERACTIONS WITH C. NEOFORMANS$403,036
R01 · FY2002 · AI
IMMUNE RESPONSE TO CRYPTOCOCCAL INFECTIONS$340,933
R01 · FY2002 · AI
IMMUNE RESPONSE TO CRYPTOCOCCAL INFECTIONS$331,077
R01 · FY2001 · AI
MACROPHAGE INTERACTIONS WITH C. NEOFORMANS$315,000
R01 · FY2001 · AI
MACROPHAGE INTERACTIONS WITH C. NEOFORMANS$35,372
R01 · FY2001 · AI
IMMUNE RESPONSE TO CRYPTOCOCCAL INFECTIONS$321,506
R01 · FY2000 · AI
MACROPHAGE INTERACTIONS WITH C NEOFORMANS$247,106
R01 · FY2000 · AI
(1. CHLOROQUINE AS IMMUNOTHERAPTY FOR CRYPTOCOCCOSIS$31,900
R03 · FY2000 · TW